Autologous chimeric antigen receptor (CAR)-T cell therapies induce durable remissions and
improve survival in patients with advanced B cell malignancies. However, challenges such …

Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR)
mediate high rates of complete response (CR) in patients with B-cell malignancies …

Centre for Haematology, Imperial College London, United Kingdom,* Arovella Therapeutics
Ltd, Victoria, Australia 1. https://www. ncbi. nlm. nih. gov/pmc/articles/PMC5743650/2 …

The announcement in late August that the US Food and Drug Administration (FDA)
approved Kymriah (tisagenlecleucel), 1 an autologous chimeric antigen receptor (CAR) T …

Despite transforming the management of patients with haematological malignancies,
autologous chimeric antigen receptor (CAR) T cell therapies have limitations. Now, the …

Off‐the‐shelf T and NK cell‐based strategies are the of future allogeneic cellular therapies,
as they overcome most of the current limitations associated with classical CAR‐T cell …

Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in
achieving a complete remission in a range of B-cell malignancies, most notably B-acute …

Despite the success of autologous anti-CD19 CAR T cell therapy in B-Acute lymphoblastic
leukaemia (B-ALL) and Diffuse Large B Cell Lymphoma (DLBCL), treatment failures occur …

Chimeric antigen receptor (CAR) expressing T cells (CAR-Ts) have demonstrated
tremendous clinical success, especially when targeted against the B-phenotypic antigens …

Background: Adoptive engineered autologous cellular immunotherapy has had a significant
impact on the lives of some patients with advanced hematologic malignancies. However, the …